Molecular Dynamics Ltd. v. Spectrum Dynamics Medical Limited

CourtDistrict Court, S.D. New York
DecidedJuly 22, 2022
Docket1:22-cv-04332
StatusUnknown

This text of Molecular Dynamics Ltd. v. Spectrum Dynamics Medical Limited (Molecular Dynamics Ltd. v. Spectrum Dynamics Medical Limited) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Molecular Dynamics Ltd. v. Spectrum Dynamics Medical Limited, (S.D.N.Y. 2022).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK

MOLECULAR DYNAMICS LTD., Plaintiff, 22 Civ. 4332 (PAE) ~ ORDER SPECTRUM DYNAMICS MEDICAL LIMITED, et al., Defendants.

PAUL A. ENGELMAYER, District Judge: On June 10, 2022, the Court granted the motion of plaintiff Molecular Dynamics Lid. (“MD”) for a preliminary injunction against defendants Spectrum Dynamics Medical Limited (“Spectrum”) and Biosensors International Group Ltd. (“Biosensors”). It enjoined them from enforcing an arbitral award against MD outside of New York, based on a forum selection clause in one of a suite of four agreements that the parties had signed.’ See Dkt. 37. The preliminary injunction was granted subject to further briefing by the parties. The Court directed defendants to file briefs in opposition to the continuation of the preliminary injunction within two weeks, and MD to respond, See id. On June 24, 2022, defendants timely filed their briefs in opposition to the continuation of the preliminary injunction, and a supporting declaration. Dkts. 46 (“Spectrum Opp.”), 47 (“Hall Taylor Decl.”), 48 (“Biosensors Opp.”). On July 8, 2022, MD responded. Dkt. 52 (“MD Resp.”). Because the Court finds that the doctrine of judicial estoppel would likely bar MD’s claims, the Court dissolves the preliminary injunction.

' The same day, the Court denied MD’s motion to remand the case to state court. See Dkt. 37. That decision is not at issue here.

I. Relevant Background and Procedural History’ This action arises from MD’s loss in an arbitration in Switzerland in which its adversaries were the two corporate defendants here. On October 15, 2013, the parties and other entities entered into a set, or as the parties have referred to it, a “suite,” of four contracts. Biosensors Mem. at 6, 8. One of them, the “License Agreement,” stated, in Section 9, that “on matters of [sic] concerning the Chosen Arbitration, the courts of New York, New York will have exclusive jurisdiction thereupon.” MD Mem. at 3. Three other agreements were also signed; the parties to those included Chauncey Capital Corp. (“Chauncey”) and SDBM, Ltd. (“SDBM”), which controlled MD. See Biosensors Mem. at 8-12, In 2018, Spectrum brought an arbitration against MD, SDBM, and Chauncey. /d. at 7. On July 31, 2019, during the arbitration, MD, Chauncey, and SDBM obtained an ex parte interim freezing order of Spectrum’s assets, pending the award from the tribunal, on the ground that Spectrum would dissipate its assets. Spectrum Opp. at 3. On April 8, 2020, the order was vacated. fd. at 7; Spectrum Mem. at 7. That proceeding is what gives rise to defendants’ assertion of judicial estoppel! here. On May 18, 2022, the arbitral panel issued its award, finding largely in favor of the defendants here (the “Award”). Spectrum Mem, at 2-3. As of May 22, 2022, the total amount that MD owed on the Award was $11,243,178. Biosensors Mem, at 16. On May 25, 2022, MD filed for a temporary restraining order (“TRO”) in New York State court seeking emergency relief to prevent one or both defendants from initiating judicial

* The facts here are drawn from MD’s memorandum of law in support of a temporary restraining order and preliminary injunction, Dkt. 8 (“MD Mem.”), Biosensors’s brief in opposition, Dkt. 17 (“Biosensors Mem.”), and Spectrum’s brief in opposition, Dkt. 22 (“Spectrum Mem.”).

proceedings outside New York, presumably to confirm the arbitral award. The next day, Spectrum and Biosensors removed the action to this Court, a few minutes before the TRO hearing set in state court. See Dkt. 1. On May 27, 2022, MD sought, and this Court granted, a TRO. Dkt. 12. The TRO as sought and granted enjoined defendants from initiating or continuing any judicial proceeding concerning the arbitration, including proceedings to recognize, confirm, or enforce the award, other than in the courts of New York. The Court did so based on MD’s showing that the License Agreement explicitly gives the New York courts exclusive jurisdiction over any matters concerning the arbitration. On that basis, the Court found, MD was likely to succeed on the merits of its claim that a confirmation proceeding outside of New York would breach MD’s contractual rights. The Court also found that MD would likely suffer irreparable harm were defendants to pursue enforcement of the arbitral award elsewhere; and that the balance of the equities also favored entry of the TRO. See id. On June 10, 2022, the Court granted MD’s motion for a preliminary injunction, pending reassessment following further briefing. Dkt. 37; see Dkt. 40 (transcript). As the transcript of the bench ruling reflects, the Court distinguished between proceedings to confirm or enforce the Award, which it concluded were likely covered by the forum selection clause, and proceedings to enforce a court judgment arising from confirmation of the Award, which likely were not. i. Discussion “The decision whether to modify a preliminary injunction involves an exercise of the same discretion that a court employs in an initial decision to grant or deny a preliminary injunction.” Weight Watchers Int'l, Inc. v. Luigino’s, Inc., 423 F.3d 137, 141 (2d Cir. 2005) (citing Sierra Club v. U.S. Army Corps of Eng’rs, 732 F.2d 253, 256 (2d Cir. 1984)). Defendants make two arguments against the continuation of the preliminary injunction as it currently stands,

First, they argue that MD is judicially estopped from pursuing the argument it successfully made here, based on the forum selection clause. Second, they argue that, based on the parties’ agreements, the Court should modify and clarify the injunction to apply only to MD, and not to other parties to the suite of agreements—namely, SDBM and Chauncey. Finding the first argument persuasive, the Court need not consider the second. In this Circuit, judicial estoppel typically applies where: (1) “a party’s later position is clearly inconsistent with its earlier position”; (2) “the party’s former position has been adopted in some way by the court in the earlier proceeding”; and (3) “the party asserting the two positions would derive an unfair advantage against the party seeking estoppel.” Penberthy v. Chickering, No. 15 Civ. 7613 (PAE), 2017 WL 176312, at *7 (S.D.N.Y. Jan. 13, 2017) (quoting DeRosa y. Envelope Corp., 595 F.3d 99, 103 (2d Cir. 2010) (citation omitted)). The Supreme Court has stated that, “[iJn enumerating these factors, we do not establish inflexible prerequisites or an exhaustive formula for determining the applicability of judicial estoppel. Additional considerations may inform the doctrine’s application in specific factual contexts.” New Hampshire v. Maine, 532. U.S. 742, 751 (2001). The Second Circuit further limits judicial estoppel “to situations where the risk of inconsistent results with its impact on judicial integrity is certain.” DeRosa, 595 F.3d at 103 (quoting Uzdavines v. Weeks Marine, Inc., 418 F.3d 138, 148 (2d Cir. 2005)); see Fed. Deposit Ins. Corp. v. Murex LLC, 500 F. Supp. 3d 76, 104 (S.D.N.Y. 2020). Here, defendants argue that they are entitled to judicial estoppel based on a position MD took before a court in the British Virgin Islands (the “BVI court”) in the course of its successful

mid-arbitration application for an ex parte freezing order of Spectrum’s assets.’ According to defendants, MD sought and received emergency relief on the explicit premise that an arbitral award in MD’s favor would be enforceable in the BVI. Spectrum Opp. at 1.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Lia v. Saporito
541 F. App'x 71 (Second Circuit, 2013)
Adelphia Recovery Trust v. Goldman, Sachs & Co.
748 F.3d 110 (Second Circuit, 2014)
Robert DeRosa v. National Envelope Corporation
595 F.3d 99 (Second Circuit, 2010)
Donnay USA Ltd. v. Donnay International S.A.
705 F. App'x 21 (Second Circuit, 2017)
Ashmore v. Cgi Grp., Inc.
923 F.3d 260 (Second Circuit, 2019)
Reed Elsevier, Inc. v. Muchnick
176 L. Ed. 2d 18 (Supreme Court, 2010)
Uzdavines v. Weeks Marine, Inc.
418 F.3d 138 (Second Circuit, 2005)
Clark v. AII Acquisition, LLC
886 F.3d 261 (Second Circuit, 2018)
Jalee Consulting Group, Inc. v. Xenoone, Inc.
908 F. Supp. 2d 387 (S.D. New York, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
Molecular Dynamics Ltd. v. Spectrum Dynamics Medical Limited, Counsel Stack Legal Research, https://law.counselstack.com/opinion/molecular-dynamics-ltd-v-spectrum-dynamics-medical-limited-nysd-2022.